Discontinuing GLP-1 receptor agonist therapy leads to predictable physiological changes as drug levels decline and the pharmacological effects diminish
Diabetes and high blood pressure are the leading causes of CKD, so people with high blood pressure or blood glucose levels need to be particularly vigilant about monitoring their kidney function
Over longer periods (3-4 weeks to a month), more visible changes in body composition (lean mass gains, fat loss) and energy tend to emerge
The regulation of GLP-1 secretion both in humans [44] and at the cellular level [45] has been studied but, except for the finding that ingestion of whey protein as a preload 30 min before a meal augments the GLP-1 response, with clinical benefits for type 2 diabetes [46], it has been difficult to translate the knowledge gained into clinically relevant formulations
They are specifically designed to support individuals with specific criteria, including: It is important to note that these medications require medical supervision to ensure safe and effective use
Research Evidence Growth Hormone Stimulation Studies The foundational 1984 study by Bowers and colleagues in Endocrinology demonstrated that GHRP-6 specifically elicited a dose-dependent release of GH in vitro and in vivo without concomitant release of LH, FSH, TSH, or prolactin at standard doses
